We are very grateful to the following corporate partners for all they do to support our work and our community.
Novartis has supported Retina UK through project funding and event sponsorship.
PROQR has supported Retina UK through project funding and event sponsorship. Their research and development pipeline includes pre-clinical and clinical trials relating to Leber congenital amaurosis (LCA) 10, Usher syndrome type 2a and autosomal dominant RP caused by a particular mutation in the rhodopsin (RHO) gene.
Santen Pharmaceutical, the specialized company dedicated to ophthalmology, has committed to developing advanced therapies that address unmet needs in orphan ophthalmic diseases. Its primary focus is on accelerating the retinitis pigmentosa program for a human retinal progenitor cell (hRPC) therapy. Santen’s vision for 2030 is to reduce the loss of social and economic opportunities for people around the world living with eye conditions.
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has established a new focus on Retinal Diseases to develop transformational therapies and platforms that restore and preserve vision. This new focus expands Johnson & Johnson’s already broad ophthalmic footprint, and includes a pipeline of innovative treatments for inherited retinal diseases and more common retinal diseases affecting millions of people worldwide.
We’d love to hear from you if you are interested in working with us. We take a flexible and personalised approach to our relationships with corporate supporters – give our friendly fundraising team a call on 01280 815900 or email fundraising@RetinaUK.org.uk for an informal chat.